Rezpegaldesleukin - Nektar Therapeutics
Alternative Names: IL-2 conjugate; Interleukin-2 conjugate; LY-3471851; NKTR-358; PEG-conjugated rhIL-2; REZPEG - Nektar TherapeuticsLatest Information Update: 08 Mar 2025
At a glance
- Originator Nektar Therapeutics
- Developer Eli Lilly and Company; Nektar Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Interleukins; Polyethylene glycols; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Interleukin 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alopecia areata; Atopic dermatitis; Systemic lupus erythematosus
- Discontinued Psoriasis; Ulcerative colitis
Most Recent Events
- 26 Feb 2025 Nektar Therapeutics completes enrolment of patients in phase II REZOLVE-AA clinical trials in Alopecia areata in Poland, Canada and USA (SC) (NCT06340360)
- 24 Feb 2025 Nektar Therapeutics plans a phase II trial for Type 1 diabetes mellitus
- 10 Feb 2025 Nektar therapeutics receives fast track desgination for Atopic dermatitis in USA